<DOC>
	<DOCNO>NCT01681446</DOCNO>
	<brief_summary>The purpose study determine whether interferon-alpha effective treatment low miR-26 expression patient HCC curative resection .</brief_summary>
	<brief_title>The Effect Postoperative Interferon- Alpha Treatment Low miR-26 Expression Patients With HCC</brief_title>
	<detailed_description>BACKGROUND : Postoperative interferon-alpha ( IFN-alpha ) therapy improve survival patient hepatocellular carcinoma ( HCC ) . MiR-26 predictive marker efficiency postoperative interferon-alpha treatment patient HCC . Our study identify Efficiency Postoperative IFN-Alpha Treatment low miR-26 expression Patients With HCC . METHODS : A quantitative reverse-transcriptase-polymerase-chain-reaction assay miR-26 perform specimen collect patient underwent curative resection HCC . These patient low miR-26 expression return hospital 25±5 day resection follow baseline examination . If requirement satisfy , patient randomly divide treatment group receive postoperative IFN-alpha therapy comparison group receive treatment . Besides disease-free survival rate , overall survival rate , time recurrence side effect observe . Anticipated RESULTS : IFN alpha treatment improved disease-free survival overall survival low miR-26 expression patient HCC curative resection , probably postpone recurrence .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Perioperative Period 1 . Signed informed consent ; 2 . Aged ≥ 18 year ≤ 75 year old , male female； 3 . Patients low miR26 expression ( confirm RTPCR ) underwent curative resection HCC ; 4 . The tumor characteristic must meet following : 1. tumor diameter 3 8 centimeter , number tumor less tnan 3 2. thrombosis detect main branch portal vein , hepatic vein bile duct 3. extrahepatic lymphnode metastasis Perioperative Period 1 . Concomitant malignant primary tumor ( ) system is/are present ; 2 . The subject receive previous systemic antiHCC therapy prior resection surgery ( except resection surgery ) , liver transplantation , intervention , ablation , radiotherapy , chemotherapy , molecular target therapy antiHCC therapy ; 3 . The subject take study/investigational drug study ; 4 . The subject cerebrovascular accident , renal insufficiency , depression , hyperthyreosis , hypothyroidism severe uncontrolled disease ; 5 . The subject history study drug similar drug allergy . Baseline ( PostSurgeryDay 25 ± 5 ) 1 . Baseline ( postresection ) blood routine examination show number leukocyte &gt; 2.5*10^9/L platelet count &gt; 40*10^9/L ; 2 . ChildPugh score class A baseline . Baseline ( PostSurgeryDay 25 ± 5 ) 1 . Concomitant malignant primary tumor ( ) system is/are present ; 2 . The subject take study/investigational drug within 4 week prior randomization ; 3 . The baseline examination indicate infection , bleeding , bile leakage , postoperative complication present ; 4 . The baseline examination suggest presence tumor metastasis ; 5 . The subject cerebrovascular accident , renal insufficiency , depression , hyperthyreosis , hypothyroidism severe uncontrolled disease ; 6 . The subject history investigational drug similar drug allergy ; 7 . The subject pregnant , lactating , urine pregnancy test result positive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>interferon-alpha</keyword>
	<keyword>miR-26</keyword>
</DOC>